Relapsed or Refractory B Cell Malignancies Market

Purchase Option

$ 4400
$ 6600
$ 8900

Relapsed or Refractory B Cell Malignancies Market Segmentation

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Relapsed/refractory B cell Malignancies Market Introduction
2.1.Global Relapsed/refractory B cell Malignancies Market - Taxonomy
2.2.Global Relapsed/refractory B cell Malignancies Market - Definitions
2.2.1.By Drug
2.2.2.By Distribution Channel
2.2.3.By Region
3.Global Relapsed/refractory B cell Malignancies Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Relapsed/refractory B cell Malignancies Market Analysis, 2018-2022 and Forecast 2023-2029
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5.Global Relapsed/refractory B cell Malignancies Market By Drug, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Epkinly
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Monjuvi
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. XPOVIO
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Polivy
5.4.1.Polivy Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Kymriah
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Yescarta
5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Others
5.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
6.Global Relapsed/refractory B cell Malignancies Market By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Hospital Pharmacy
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Retail Pharmacy
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Online Pharmacy
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7.Global Relapsed/refractory B cell Malignancies Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Europe
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Asia Pacific (APAC)
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Latin America
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
7.5. Middle East and Africa
7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.5.3. Market Opportunity Analysis
8.North America Relapsed/refractory B cell Malignancies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. Drug Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.1.1.Epkinly
8.1.2.Monjuvi
8.1.3.XPOVIO
8.1.4.Polivy
8.1.5.Kymriah
8.1.6.Yescarta
8.1.7.Others
8.2. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.2.1.Hospital Pharmacy
8.2.2.Retail Pharmacy
8.2.3.Online Pharmacy
8.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
8.3.1.United States of America (USA)
8.3.2.Canada
9.Europe Relapsed/refractory B cell Malignancies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Drug Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1.Epkinly
9.1.2.Monjuvi
9.1.3.XPOVIO
9.1.4.Polivy
9.1.5.Kymriah
9.1.6.Yescarta
9.1.7.Others
9.2. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1.Hospital Pharmacy
9.2.2.Retail Pharmacy
9.2.3.Online Pharmacy
9.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1.Germany
9.3.2.France
9.3.3.Italy
9.3.4.United Kingdom (UK)
9.3.5.Spain
9.3.6.Rest of EU
10.Asia Pacific (APAC) Relapsed/refractory B cell Malignancies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Drug Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1.Epkinly
10.1.2.Monjuvi
10.1.3.XPOVIO
10.1.4.Polivy
10.1.5.Kymriah
10.1.6.Yescarta
10.1.7.Others
10.2. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1.Hospital Pharmacy
10.2.2.Retail Pharmacy
10.2.3.Online Pharmacy
10.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1.China
10.3.2.India
10.3.3.Australia and New Zealand (ANZ)
10.3.4.Japan
10.3.5.Rest of APAC
11.Latin America Relapsed/refractory B cell Malignancies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Drug Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1.Epkinly
11.1.2.Monjuvi
11.1.3.XPOVIO
11.1.4.Polivy
11.1.5.Kymriah
11.1.6.Yescarta
11.1.7.Others
11.2. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1.Hospital Pharmacy
11.2.2.Retail Pharmacy
11.2.3.Online Pharmacy
11.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1.Brazil
11.3.2.Mexico
11.3.3.Rest of LA
12.Middle East and Africa Relapsed/refractory B cell Malignancies Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Drug Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.1.1.Epkinly
12.1.2.Monjuvi
12.1.3.XPOVIO
12.1.4.Polivy
12.1.5.Kymriah
12.1.6.Yescarta
12.1.7.Others
12.2. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.2.1.Hospital Pharmacy
12.2.2.Retail Pharmacy
12.2.3.Online Pharmacy
12.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.3.1.GCC Countries
12.3.2.South Africa
12.3.3.Rest of MEA
13. Competition Landscape
13.1. Market Player Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Collaborations, Strategies, and SWOT Analysis)
13.2.1.AbbVie
13.2.2.Karyopharm Therapeutics
13.2.3.MorphoSys US Inc.
13.2.4.Bristol Myers Squibb
13.2.5.Merck & Co., Inc.
13.2.6.Gilead Sciences, Inc.
13.2.7.Novartis AG
13.2.8.Incyte
13.2.9.F. Hoffmann-La Roche AG
14. Research Methodology
15. Appendix and Abbreviations
• AbbVie
• Karyopharm Therapeutics
• MorphoSys US Inc.
• Bristol Myers Squibb
• Merck & Co., Inc.
• Gilead Sciences, Inc.
• Novartis AG
• Incyte
• F. Hoffmann-La Roche AG

Adjacent Markets